172 related articles for article (PubMed ID: 36082407)
21. Discovery and Validation of Serum MicroRNAs as Early Diagnostic Biomarkers for Prostate Cancer in Chinese Population.
Lyu J; Zhao L; Wang F; Ji J; Cao Z; Xu H; Shi X; Zhu Y; Zhang C; Guo F; Yang B; Sun Y
Biomed Res Int; 2019; 2019():9306803. PubMed ID: 31534967
[TBL] [Abstract][Full Text] [Related]
22. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
23. Affinity Captured Urinary Extracellular Vesicles Provide mRNA and miRNA Biomarkers for Improved Accuracy of Prostate Cancer Detection: A Pilot Study.
Davey M; Benzina S; Savoie M; Breault G; Ghosh A; Ouellette RJ
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33172003
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of epi-miRNA expression levels in local/locally advanced and metastatic prostate cancer patients.
Gurbuz V; Kiliccioglu I; Dikmen AU; Bilen CY; Sozen S; Konac E
Gene; 2020 Oct; 758():144963. PubMed ID: 32683077
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
[TBL] [Abstract][Full Text] [Related]
26. Small RNAs as biomarkers to differentiate benign and malign prostate diseases: An alternative for transrectal punch biopsy of the prostate?
Markert L; Holdmann J; Klinger C; Kaufmann M; Schork K; Turewicz M; Eisenacher M; Savelsbergh A
PLoS One; 2021; 16(3):e0247930. PubMed ID: 33760831
[TBL] [Abstract][Full Text] [Related]
27. miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer.
Ghorbanmehr N; Gharbi S; Korsching E; Tavallaei M; Einollahi B; Mowla SJ
Prostate; 2019 Jan; 79(1):88-95. PubMed ID: 30194772
[TBL] [Abstract][Full Text] [Related]
28. Activin A regulates microRNAs and gene expression in LNCaP cells.
Ottley EC; Nicholson HD; Gold EJ
Prostate; 2016 Aug; 76(11):951-63. PubMed ID: 27018851
[TBL] [Abstract][Full Text] [Related]
29. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
30. The utility of urine-circulating miRNAs for detection of prostate cancer.
Stuopelyte K; Daniunaite K; Bakavicius A; Lazutka JR; Jankevicius F; Jarmalaite S
Br J Cancer; 2016 Sep; 115(6):707-15. PubMed ID: 27490805
[TBL] [Abstract][Full Text] [Related]
31. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
Jin W; Fei X; Wang X; Chen F; Song Y
J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
[TBL] [Abstract][Full Text] [Related]
32. Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
Tinay I; Tan M; Gui B; Werner L; Kibel AS; Jia L
Prostate; 2018 Sep; 78(12):927-937. PubMed ID: 29748958
[TBL] [Abstract][Full Text] [Related]
33. Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (
Fredsøe J; Rasmussen AKI; Laursen EB; Cai Y; Howard KA; Pedersen BG; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
Clin Chem; 2019 Apr; 65(4):540-548. PubMed ID: 30728149
[TBL] [Abstract][Full Text] [Related]
34. Virus encoded circulatory miRNAs for early detection of prostate cancer.
Kim J; Yun SJ; Kim WJ
BMC Urol; 2015 Nov; 15():116. PubMed ID: 26612689
[TBL] [Abstract][Full Text] [Related]
35. Identification of microRNA signature and potential pathway targets in prostate cancer.
Moustafa AA; Ziada M; Elshaikh A; Datta A; Kim H; Moroz K; Srivastav S; Thomas R; Silberstein JL; Moparty K; Salem FE; El-Habit OH; Abdel-Mageed AB
Exp Biol Med (Maywood); 2017 Mar; 242(5):536-546. PubMed ID: 27903835
[TBL] [Abstract][Full Text] [Related]
36. Seminal plasma microRNAs improve diagnosis/prognosis of prostate cancer in men with moderately altered prostate-specific antigen.
Barceló M; Castells M; Pérez-Riba M; Bassas L; Vigués F; Larriba S
Am J Transl Res; 2020; 12(5):2041-2051. PubMed ID: 32509198
[TBL] [Abstract][Full Text] [Related]
37. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.
Kang HW; Byun YJ; Moon SM; Kim K; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2022 Mar; 63(2):238-244. PubMed ID: 35244999
[TBL] [Abstract][Full Text] [Related]
38. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
39. Circulating let-7f-5p improve risk prediction of prostate cancer in patients with benign prostatic hyperplasia.
Ge Y; Wang Q; Shao W; Zhao Y; Shi Q; Yuan Q; Cui L
J Cancer; 2020; 11(15):4542-4549. PubMed ID: 32489471
[No Abstract] [Full Text] [Related]
40. A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples.
Guo J; Yang J; Zhang X; Feng X; Zhang H; Chen L; Johnson H; Persson JL; Xiao K
Anticancer Res; 2018 Mar; 38(3):1471-1477. PubMed ID: 29491074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
